After phase 2 flop, BerGenBio posts new data on COVID-19 prospect

The effort to establish bemcentinib as a COVID-19 drug continues. Eleven months after failing a phase 2 trial, BerGenBio has shared data from a second, smaller trial that linked the drug to significant changes.